TICKERNERD
Menu
SNDXSNDXHealthcare · Biotechnology

SNDX Stock Forecast: Syndax Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$20
+3.98% on the day

The 12 Wall Street analysts covering Syndax Pharmaceuticals, Inc. hold a median 12-month price target of $37 — +86.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 66 of 100 as at 15 Aug 2026 — in the upper half.

Market cap
$1.8B
Ticker Nerd rank
66 / 100
Median analyst target
$37
Analysts covering
12
Total return, dividends reinvested
1W
−2.7%
1M
−17.8%
YTD
−5.6%
1Y
+34.7%
From 52W high
−21.1%
From 52W low
+51.3%
$13
$25
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SNDX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Syndax Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
66 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
93
Growth
93
Value
92
Momentum
80
Quality
77
Size
38
Accruals
34
Revisions
33
Issuance
11

Volatility (93): The share price has been relatively steady.

Issuance (11): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SNDX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SNDX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26SNDXHigh $57Median $37Low $26

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says12 analysts
12 Buy0 Hold0 Sell
Low $26Median $37High $57

The green dot is the last close — the median target sits +86.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
11 Aug 2026JP MorganMaintainsOverweight$44 → $40
5 Aug 2026HC Wainwright & Co.MaintainsBuy$40 → $38
15 July 2026HC Wainwright & Co.ReiteratesBuy$40
15 July 2026HC Wainwright & Co.ReiteratesBuy—
12 June 2026HC Wainwright & Co.ReiteratesBuy$40
12 June 2026HC Wainwright & Co.ReiteratesBuy—
22 May 2026HC Wainwright & Co.ReiteratesBuy—
13 May 2026UBSMaintainsBuy—
1 May 2026BarclaysMaintainsOverweight—
1 Apr 2026Goldman SachsMaintainsBuy—
31 Mar 2026MizuhoMaintainsOutperform—
30 Mar 2026JefferiesAssumesBuy$48 → $40
9 Mar 2026JP MorganMaintainsOverweight—
2 Mar 2026CitigroupMaintainsBuy—
27 Jan 2026MizuhoMaintainsOutperform$410 → $600
9 Dec 2025BTIGReiteratesBuy—
24 Nov 2025BarclaysMaintainsOverweight—
12 Nov 2025JP MorganMaintainsOverweight—
4 Nov 2025BarclaysMaintainsOverweight—
4 Nov 2025UBSMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SNDX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

SNDX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
1
Fundamentals

Syndax Pharmaceuticals, Inc. (SNDX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−6.0×

Cheaper than 90% of US stocks

Price / sales
7.0×

Cheaper than 19% of US stocks

Price / book
117.4×

Cheaper than 1% of US stocks

EV / EBITDA
−9.3×

Cheaper than 83% of US stocks

Growth & margins
Revenue growth (YoY)
91.8%

Higher than 92% of US stocks

Earnings growth (YoY)
91.8%

Higher than 83% of US stocks

Gross margin
95.6%

Higher than 99% of US stocks

Operating margin
−54.9%

Higher than 16% of US stocks

Net margin
−87.5%

Higher than 6% of US stocks

Returns & dividend
Return on equity
−255.9%

Higher than 5% of US stocks

Return on assets
−18.7%

Higher than 20% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

SNDX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SNDXSyndax Pharmaceuticals, Inc.$1.8B
66
ANABAnaptysBio, Inc.$1.7B
100
AVLNAvalyn Pharma, Inc.$1.7B
1
XNCRXencor, Inc.$1.7B
82
NTLAIntellia Therapeutics, Inc.$1.7B
53
ZYMEZymeworks, Inc.$1.8B
70
RXRXRecursion Pharmaceuticals, Inc.$1.6B
43

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Syndax Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SNDX news & analysis

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewsWire · 5 Aug 2026neutral

Syndax Pharmaceuticals announced that on August 1, 2026, it granted inducement awards to purchase up to 59,250 shares of common stock to five new employees under the company's 2023 Inducement Plan. The stock options vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th vesting monthly thereafter over 36 months, subject to continued service.

Why it matters — The inducement grants indicate new hires joining the company and represent routine equity compensation disclosed under NASDAQ Listing Rule 5635(c)(4) that SNDX watchers may track.

Syndax Pharmaceuticals, Inc. (SNDX) Q2 2026 Earnings Call Transcript

Seeking Alpha · 5 Aug 2026neutral

Syndax Pharmaceuticals released the transcript of its Q2 2026 earnings call, as published by Seeking Alpha. The transcript covers the company's earnings call discussion for the quarter.

Why it matters — A SNDX watcher would care because the transcript offers direct insight into management's commentary on the company's quarterly results.

Syndax Pharmaceuticals Q2 Earnings Call Highlights

MarketBeat · 5 Aug 2026positive

Syndax Pharmaceuticals reported second-quarter 2026 total revenue of $72.8 million, up 92% from the prior-year period, driven by continued sales growth of its leukemia treatment Revuforj and its chronic graft-versus-host disease therapy Niktimvo.

Why it matters — A Syndax watcher would care because the strong year-over-year revenue increase points to growing commercial traction for its two marketed therapies.

Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research · 4 Aug 2026negative

Syndax Pharmaceuticals reported a Q2 loss of $0.55 per share, wider than the Zacks Consensus Estimate of a $0.45 loss, though narrower than the $0.83 loss from the same quarter last year.

Why it matters — The quarterly loss exceeded analyst expectations, which could raise concerns about the company's near-term financial performance.

Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 4 Aug 2026positive

Syndax Pharmaceuticals reported second quarter 2026 financial results, with total revenue of $73 million (up 92% year-over-year), Revuforj net revenue of $54.7 million, and Niktimvo net revenue of $60.3 million resulting in $18.1 million of collaboration revenue. The company also expanded its pipeline with a mutant-selective allosteric EGFR inhibitor and a next-generation menin inhibitor, and expects topline data in 4Q26 from Phase 2 trials of axatilimab in IPF and frontline cGVHD.

Why it matters — The results show strong year-over-year revenue growth from both commercial products, an expanded pipeline, and a near-term data catalyst in 4Q26 for SNDX watchers.

FAQ

Frequently asked questions about SNDX stock

What is the SNDX stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Syndax Pharmaceuticals, Inc. have a median 12-month price target of $37, with estimates ranging from $26 to $57. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SNDX stock a buy right now?

Of the 12 analysts covering Syndax Pharmaceuticals, Inc., 12 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Syndax Pharmaceuticals, Inc. 66 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SNDX?

As at 15 Aug 2026, Syndax Pharmaceuticals, Inc. ranks 66 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (93 of 100).

Will SNDX stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +86.5% from the last close, and Ticker Nerd's factor model ranks Syndax Pharmaceuticals, Inc. 66 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SNDX stock forecast for 2030?

No analyst covering Syndax Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SNDX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $26 to $57 over the next 12 months.

How has SNDX stock performed over the past year?

Syndax Pharmaceuticals, Inc. returned +34.7% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Syndax Pharmaceuticals, Inc. do?

Syndax Pharmaceuticals Inc. is a commercial stage oncology innovator focused on developing cancer therapies for areas of significant unmet medical need.

What is the latest news on SNDX?

The most recent item we track (GlobeNewsWire, 5 Aug 2026): "Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)". Syndax Pharmaceuticals announced that on August 1, 2026, it granted inducement awards to purchase up to 59,250 shares of common stock to five new employees under the company's 2023 Inducement Plan. The stock options vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th vesting monthly thereafter over 36 months, subject to continued service.

Company

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals Inc. is a commercial stage oncology innovator focused on developing cancer therapies for areas of significant unmet medical need. The company's product portfolio includes Revuforj, a menin inhibitor approved for treating relapsed or refractory NPM1-mutated acute myeloid leukemia in adult and pediatric patients, along with Niktimvo, an axatilimab-based therapeutic. The company also operates proprietary platforms including SyndAccess and IncyteCARES, which support its drug development and patient care initiatives. Syndax Pharmaceuticals targets oncologists and patients dealing with acute leukemias and related hematologic malignancies, positioning itself within the biotechnology sector as a specialized pharmaceutical developer addressing critical gaps in cancer treatment. Founded in 2005 and headquartered in New York, the company combines research-stage development capabilities with commercial product distribution to serve the global oncology market.

CEO Mr. Michael A. Metzger M.B.A. · 298 employees · United States · https://syndax.com